The case for & against
Bull & Bear analysis
Bullish
Mursana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company specializing in developing innovative therapies focused on antibody-drug conjugates (ADCs) for oncology. The company's lead candidates include Emily, targeting B7H4 in triple-negative breast cancer (TNBC) and XMT2056 for HER2-positive tumors. Positioned within the oncology therapeutics revolution, Mursana aims to address significant unmet medical needs in various cancer types by leveraging advanced technologies in ADC formulations.
Bull says
- ↑31% objective response rate in high B7H4 TNBC underscores Emily’s efficacy
- ↑$77M cash runway extends funding for clinical programs into mid-2026
- ↑Q2 operating burn cut to $22.6M reflects disciplined cost management
- ↑Q2 collaboration revenue rose to $3.1M, driven by partnerships with J&J and Merck
- ↑Competitor B7H4 ADC exit expands Emily’s addressable patient pool
- ↑Distinct ADC mechanism may bypass topo1 resistance, aiding market adoption
Bear says
- ↓Collaboration revenue plunged from $9.2M in Q1’24 to $2.8M in Q1’25, pressuring liquidity
- ↓Q1 net loss widened to $24.1M, accelerating cash depletion risk
- ↓Maximum tolerated dose still undefined, heightening trial execution uncertainty
- ↓Proteinuria adverse events may reduce patient adherence and delay trials
- ↓Intense ADC competition could overshadow Mursana’s clinical candidates
- ↓Heavy reliance on partner revenue and future capital raises risks dilution
Earnings Call · Q2 2024 · Mgmt. Guidance
Updated 09-11-2026neutral
Transcript signals
Bull points
- We continue to expect our available funds will support our operating plan commitments into 2026.
- Net cash used in operating activities for the second quarter of 2024 was $21.8 million, down significantly from the $61.8 million in net cash used during the year-ago quarter, reflecting our effective cost control measures. The year-over-year decline in R&D expenses was primarily related to reduced costs associated with manufacturing and clinical activities for our discontinued ADC UPRI and reduced employee compensation expense following the restructuring we completed in 2023.
- XMT1660
Bear points
- With regards to your second question, we are now getting purely into speculation as we have not had, you know, we're not coming forward with a specified registration enabling study. So I want to be clear what I'm giving you is a theoretical.
- We're keeping the guidance at second half. That could be a company event or it could be a medical congress. At this stage, we haven't defined that.
- The step we're left is the identification of a recommended phase to at least one recommended phase two dose to take forward into the expansion. And as we have not yet defined an MTD, we are not ready to declare a recommended phase two dose at this point in time.
Read full transcript analysis ›